Kanaph Therapeutics to Participate in 'BIO USA 2026'... Accelerating Business Development Discussions

Kanaph Therapeutics will participate in the world’s largest bio event, the 'BIO International Convention 2026 (BIO USA),' to be held in San Diego, USA, from June 22 to 25.

According to Kanaph Therapeutics on June 16, the company has received partnering meeting requests from more than 20 global pharmaceutical and biotech companies for this event. CEO Lee Byungcheol and Head of Business Development Yoon Youngsoo will attend in person to discuss business development opportunities.

Kanaph Therapeutics is expanding its global reach based on the research and development achievements of its pipeline. Notably, according to data recently released at major conferences including AACR and ARVO, KNP-301 has demonstrated VEGF inhibitor activity comparable to standard therapies for wet age-related macular degeneration, as well as competitive complement inhibition efficacy compared to standard therapies for geographic atrophy. As a result, it is receiving attention as a new option among next-generation therapies that can simultaneously target both wet age-related macular degeneration and geographic atrophy. In addition, KNP-101 has shown the potential to minimize systemic toxicity while maintaining anti-tumor immune activity within tumors, even in repeated dosing scenarios.

A representative from Kanaph Therapeutics stated, "BIO USA is an important venue for discussing specific business collaboration strategies with potential partners," adding, "With growing global interest in our diverse pipeline, we aim to achieve tangible business development results through this event."

This content was produced with the assistance of AI translation services.